Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.
Thomson SA, Banker P, Bickett DM, Boucheron JA, Carter HL, Clancy DC, Cooper JP, Dickerson SH, Garrido DM, Nolte RT, Peat AJ, Sheckler LR, Sparks SM, Tavares FX, Wang L, Wang TY, Weiel JE. Thomson SA, et al. Among authors: tavares fx. Bioorg Med Chem Lett. 2009 Feb 15;19(4):1177-82. doi: 10.1016/j.bmcl.2008.12.085. Epub 2008 Dec 25. Bioorg Med Chem Lett. 2009. PMID: 19138846
Amino acid anthranilamide derivatives as a new class of glycogen phosphorylase inhibitors.
Evans KA, Li YH, Coppo FT, Graybill TL, Cichy-Knight M, Patel M, Gale J, Li H, Thrall SH, Tew D, Tavares F, Thomson SA, Weiel JE, Boucheron JA, Clancy DC, Epperly AH, Golden PL. Evans KA, et al. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4068-71. doi: 10.1016/j.bmcl.2008.05.102. Epub 2008 Jun 12. Bioorg Med Chem Lett. 2008. PMID: 18554908
The discovery and optimization of pyrimidinone-containing MCH R1 antagonists.
Hertzog DL, Al-Barazanji KA, Bigham EC, Bishop MJ, Britt CS, Carlton DL, Cooper JP, Daniels AJ, Garrido DM, Goetz AS, Grizzle MK, Guo YC, Handlon AL, Ignar DM, Morgan RO, Peat AJ, Tavares FX, Zhou H. Hertzog DL, et al. Among authors: tavares fx. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4723-7. doi: 10.1016/j.bmcl.2006.07.008. Epub 2006 Jul 25. Bioorg Med Chem Lett. 2006. PMID: 16870432
Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.
Sparks SM, Banker P, Bickett DM, Carter HL, Clancy DC, Dickerson SH, Dwornik KA, Garrido DM, Golden PL, Nolte RT, Peat AJ, Sheckler LR, Tavares FX, Thomson SA, Wang L, Weiel JE. Sparks SM, et al. Among authors: tavares fx. Bioorg Med Chem Lett. 2009 Feb 1;19(3):976-80. doi: 10.1016/j.bmcl.2008.11.085. Epub 2008 Nov 27. Bioorg Med Chem Lett. 2009. PMID: 19095442
Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.
Sparks SM, Banker P, Bickett DM, Clancy DC, Dickerson SH, Garrido DM, Golden PL, Peat AJ, Sheckler LR, Tavares FX, Thomson SA, Weiel JE. Sparks SM, et al. Among authors: tavares fx. Bioorg Med Chem Lett. 2009 Feb 1;19(3):981-5. doi: 10.1016/j.bmcl.2008.11.084. Epub 2008 Nov 27. Bioorg Med Chem Lett. 2009. PMID: 19095443
Novel and potent cyclic cyanamide-based cathepsin K inhibitors.
Deaton DN, Hassell AM, McFadyen RB, Miller AB, Miller LR, Shewchuk LM, Tavares FX, Willard DH Jr, Wright LL. Deaton DN, et al. Among authors: tavares fx. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1815-9. doi: 10.1016/j.bmcl.2005.02.033. Bioorg Med Chem Lett. 2005. PMID: 15780613
23 results